Frontline Treatment of Chronic Lymphocytic Leukemia with Continuous Bruton's Tyrosine Kinase Inhibitors: A Comprehensive Overview.

Abstract

Continuous treatment with Bruton's tyrosine kinase (BTK) inhibitors is well established for chronic lymphocytic leukemia in the frontline setting. Long-term data shows near-normal life expectancy for patients who are treated with ibrutinib. Second-generation BTK inhibitors have improved tolerability compared to ibrutinib and continue to show long-term durable remissions. Time-limited treatments with venetoclax combined with obinutuzumab or a BTK inhibitor demonstrate durable disease control as well. However, achieving superior and sustained long-term outcomes compared to continuous BTK inhibitor treatment remains challenging, particularly in high-risk genomic subgroups.